Trials / Completed
CompletedNCT00928837
Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
A Double-Blind,Randomized, Placebo Controlled, Parallel Group, Multi-Center Study of Flavocoxid (Limbrel) Versuss Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 350 (actual)
- Sponsor
- Primus Pharmaceuticals · Industry
- Sex
- All
- Age
- 35 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the efficacy and safety of flavocoxid (Limbrel) with Naproxen and placebo in OA of the knee.
Detailed description
To compare the efficacy, safety, quality of life and economic impact of flavocoxid vs naproxen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Flavocoxid 500 mg | flavonoid mixture |
| DRUG | Naproxen | non-steroidal anti-inflammatory drug |
| OTHER | Placebo | Placebo |
| OTHER | flavocoxid 250 mg | Medical food product |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2007-06-01
- Completion
- 2007-09-01
- First posted
- 2009-06-26
- Last updated
- 2017-12-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00928837. Inclusion in this directory is not an endorsement.